Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...

The Goldman Sachs equity team says it continues to recommend investors owning healthcare stocks. Healthcare "offers a ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

The deal with Regeneron comes months after CytomX Therapeutics laid off 40% of its workers. Image sourced from: Cancer Research UK / Shutterstock Nicole Raleigh ...

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.